CTLA4 and melanoma: When Imatinib within tLyp1 peptide-conjugated nanoparticles was combined with anti-CTLA-4 antibody, the authors found an enhanced downregulation of suppressive Tregs and activation of CD8+ effector T cells in the B16/B6 melanoma model [90].